Sep 12, 2022 Press Releases
PDF Version AT-01 shows increased LV uptake and LV amyloid activity in all cardiac ATTR and AL subjects, but in none of the controls (100% accuracy) AT-01 demonstrates significantly higher left ventricular uptake in ATTR-CMP participants than florbetapir SAN...
Sep 8, 2022 Press Releases
PDF Version AT-01 is a first-in-class pan-amyloid imaging agent capable of detecting diverse types of systemic amyloidosis in multiple organs Sensitivity in those with previously diagnosed cardiac disease was 100% in ATTR and 93% in AL Organ-specific changes in...
Sep 7, 2022 Press Releases
PDF Version AT-04 demonstrates potent binding and promotes phagocytosis in ATTR and AL amyloidosis AT-04 binds potently to Aβ, tau, and α-synuclein, common amyloid pathologies in CNS disorders such as Alzheimer’s SAN FRANCISCO, Calif. – September 7, 2022 –...
Aug 22, 2022 Press Releases
PDF Version SAN FRANCISCO, Calif. – August 22, 2022 – Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, today announced that new data across the Company’s...
Jun 14, 2022 Posters & Publications
PDF Version Source Author: Jonathan S. Wall, Emily B. Martin, Alan Stuckey, Dustin Powell, R. Eric Heidel, Ronald Lands, Stephen J. Kennel AUTHORS: Jonathan S. Wall, Emily B. Martin, Alan Stuckey, Dustin Powell, R. Eric Heidel, Ronald Lands, Stephen J. Kennel...
